Home
Paradigm Biocapital Advisors reported a 4.9% stake in Janux Therapeutics JANX · 2,920,258 sh · amendment · passive holder
Trade details
- Type
- 5% stake report
- Report
- 13G passive · amendment
- Stake
- 4.9%
- Last report
- 6% · filed 25/02/14
- Shares held
- 2,920,258 sh
- Class
- Common Stock, $0.001 par value per share
- Event date
- 25/06/30
- Filed
- 25/08/14
4.9% stake · below 5%
- Stake
- 4.9%
- Last report
- 6%
- Since last report
- −1.1pp
Janux Therapeutics trades, last 26 weeks
What else happened in Janux Therapeutics around then
Filed or reported within 30 days of the trade day · 25/05/31~25/07/30Paradigm Biocapital Advisors's other 5% stake reports
- Paradigm Biocapital Advisors
5% stakeSpyre Therapeutics
5% stakeSpyre Therapeutics
SYRE
5.1% stake
4,457,450 sh
5.1% stake
Filed 10/01
- Paradigm Biocapital Advisors
5% stakeTyra Biosciences
5% stakeTyra Biosciences
TYRA
5.8% stake
3,473,453 sh
5.8% stake
Filed 09/17
- Paradigm Biocapital Advisors
5% stakeAssembly Biosciences
5% stakeAssembly Biosciences
ASMB
7.8% stake
1,553,748 sh
7.8% stake
Filed 08/14
- Paradigm Biocapital Advisors
5% stakeViridian Therapeutics, Inc.\DE
5% stakeViridian Therapeutics, Inc.\DE
VRDN
6.1% stake
6,723,788 sh
6.1% stake
Filed 08/14
- Paradigm Biocapital Advisors
5% stakeLexeo Therapeutics
5% stakeLexeo Therapeutics
LXEO
5.3% stake
4,175,382 sh
5.3% stake
Filed 08/14
